Free tool
Drug Trial Radar: Kidney and urology
Last checked: Nov 20, 2026Latest source record: Nov 18, 2026 (registry update on this page)ClinicalTrials.gov last updated: Nov 20, 2026Methods & limitations
Filters
Filters are saved in the page address, so a filtered view can be bookmarked or shared.
Matching drug trials
33
Recruiting, industry sponsors, Kidney and urology, Phase 2
By trial status
The same filters, counted in each status. Pick one to switch.
- Completed288
33 trials
Showing 1 to 25, recently updated first.
ADARx Pharmaceuticals, Inc.Industry
NCT06989359 · 85 participants (planned) · Start Aug 28, 2025 · Primary completion Apr 30, 2030
Drug: ADX-038 Dose Level 2; ADX-038 Dose Level 1 and 1 more · For: IgAN; C3G; Complement-mediated Kidney Disease and 2 more
Sites: Doral, Florida; Miami, Florida; Pembroke Pines, Florida · 38 sites in all
SanofiSanofi (SNY)
NCT06500702 · 84 participants (planned) · Start Dec 19, 2024 · Primary completion Dec 23, 2026
Drug: frexalimab; brivekimig and 2 more · For: Focal Segmental Glomerulosclerosis; Glomerulonephritis Minimal Lesion
Sites: Birmingham, Alabama; Orange, California; San Francisco, California · 82 sites in all
Akebia TherapeuticsIndustry
NCT07268638 · 60 participants (planned) · Start Dec 3, 2025 · Primary completion Jun 2027
Drug: Praliciguat (Part A); Praliciguat (Part B) · For: Focal Segmental Glomerulosclerosis
Sites: Chula Vista, California; Garden Grove, California; Los Angeles, California · 32 sites in all
- UBT251 Injection Phase II Clinical Study (CKD)Pivotal-lookingRecruiting
The United Bio-Technology (Hengqin) Co., Ltd.Industry
NCT07134335 · 180 participants (planned) · Start Sep 1, 2025 · Primary completion Jul 11, 2030
Drug: UBT251; UBT251 and 1 more · For: Obesity &Amp; Overweight; Chronic Kidney Disease
Sites: Beijing, China
- Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of KP104 to Treat GlomerulonephritisRecruiting
Kira Pharmacenticals (US), LLC.Industry
NCT05517980 · 52 participants (planned) · Start Dec 1, 2025 · Primary completion Dec 2028
Drug: KP104 · For: Glomerulonephritis
Sites: Beijing, China
Atom Therapeutics Co., LtdIndustry
NCT07323095 · 80 participants (planned) · Start Oct 2, 2026 · Primary completion Oct 31, 2027
Drug: ABP-671 plus febuxostat Group 1; ABP-671 plus febuxostat Group 2 and 2 more · For: Chronic Kidney Disease
Sites: Gosford, Australia; Newcastle, Australia; Brisbane, Australia · 10 sites in all
Jade Biosciences, Inc.Industry
NCT07541287 · 30 participants (planned) · Start May 19, 2026 · Primary completion Jan 2029
Drug: JADE101 · For: IgA Nephropathy
Sites: Chula Vista, California; Arvada, Colorado; Denver, Colorado · 22 sites in all
- Study to Assess the Effects of ALN-ANG3 in Adult Participants With Diabetic Kidney DiseasePivotal-lookingRecruiting
Regeneron PharmaceuticalsRegeneron (REGN)
NCT07271186 · 195 participants (planned) · Start Jan 9, 2026 · Primary completion Oct 13, 2028
Drug: ALN-ANG3; Evinacumab and 1 more · For: Diabetic Kidney Disease (DKD)
Sites: Huntsville, Alabama; Little Rock, Arkansas; Huntington Beach, California · 59 sites in all
- A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgANPivotal-lookingRecruiting
argenxargenx (ARGX)
NCT07773727 · 120 participants (planned) · Start Nov 5, 2026 · Primary completion Oct 29, 2029
Drug: ARGX-121; Placebo · For: Immunoglobulin A Nephropathy (IgAN)
Sites: Valencia, California; Miami, Florida; Pembroke Pines, Florida · 11 sites in all
Vifor Fresenius Medical Care Renal PharmaIndustry
NCT06593392 · 18 participants (planned) · Start Aug 4, 2026 · Primary completion Aug 15, 2029
Drug: Difelikefalin · For: Pruritus; Chronic Kidney Diseases
Sites: Chengdu, China; Guangzhou, China; Hangzhou, China · 18 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT07146906 · 32 participants (planned) · Start Mar 26, 2026 · Primary completion Jul 12, 2030
Drug: zigakibart · For: Immunoglobulin A Nephropathy (IgAN)
Sites: San Francisco, California; Denver, Colorado; Acworth, Georgia · 30 sites in all
- A Study to Investigate IGT-303 in Healthy Volunteers and Participants With Chronic Kidney DiseaseRecruiting
Ingenia Therapeutics INCIndustry
NCT07231679 · 94 participants (planned) · Start Oct 30, 2025 · Primary completion Dec 2026
Drug: IGT-303; Placebo · For: Healthy Volunteers; Chronic Kidney Disease
Sites: Chula Vista, California; Lakeland, Florida; Statesville, North Carolina · 13 sites in all
Akebia TherapeuticsIndustry
NCT06419205 · 30 participants (planned) · Start Jul 30, 2026 · Primary completion Feb 2028
Drug: ADX-097 · For: IgA Nephropathy; Lupus Nephritis (LN); C3 (Complement Component 3) Glomerulopathy
Sites: Hollywood, Florida; Lawrenceville, Georgia; Orangeburg, South Carolina · 4 sites in all
Sitala Bio LTDIndustry
NCT07606352 · 15 participants (planned) · Start Aug 4, 2026 · Primary completion Jul 2027
Drug: STL303; STL303 and 1 more · For: IgAN
Sites: Newcastle, Australia; Penrith, Australia; Sydney, Australia · 8 sites in all
- Chinese Adults With Kidney DiseaseRecruiting
ADARx Pharmaceuticals, Inc.Industry
NCT07522099 · 30 participants (planned) · Start May 21, 2026 · Primary completion Jul 10, 2028
Drug: ADX-038; Telitacicept · For: Immunoglobulin A Nephropathy (IgAN); Complement 3 Glomerulopathy (C3G); IC-MPGN
Sites: Shenzhen, China; Guiyang, China; Zhengzhou, China · 9 sites in all
- A Sequential Phase 2/3 Study of APL2 in Patients With Focal Segmental GlomerulosclerosisPivotal-lookingRecruiting
Apellis Pharmaceuticals, Inc.Industry
NCT07213960 · 270 participants (planned) · Start Dec 2026 · Primary completion Oct 2029
Drug: APL2 · For: FSGS
Sites: Chicago, Illinois; New York, New York
OPKO Health, Inc.Industry
NCT07494045 · 40 participants (planned) · Start Aug 5, 2026 · Primary completion Oct 2027
Drug: CTAP101 · For: CKD Stage 3; CKD Stage 4; Secondary Hyperparathyroidism and 1 more
Sites: Kansas City, Missouri; Columbus, Ohio; Philadelphia, Pennsylvania · 5 sites in all
Everest Medicines (China) Co.,Ltd.Industry
NCT07614477 · 45 participants (planned) · Start May 20, 2026 · Primary completion Dec 31, 2028
Drug: EVER001 · For: Minimal Change Disease (MCD); IgA Nephropathy (IgAN); Focal Segmental Glomerulosclerosis (FSGS)
Sites: Beijing, China; Tianjin, China
Walden BiosciencesIndustry
NCT06466135 · 96 participants (planned) · Start Jul 2, 2024 · Primary completion Mar 2027
Drug: WAL0921; Placebo · For: Diabetic Nephropathies; Primary Focal Segmental Glomerulosclerosis; Minimal Change Disease and 2 more
Sites: Los Angeles, California; Denver, Colorado; Tamarac, Florida · 50 sites in all
Novartis PharmaceuticalsNovartis (NVS)
NCT06797518 · 20 participants (planned) · Start Feb 21, 2025 · Primary completion Nov 27, 2027
Drug: Iptacopan · For: Glomerulonephritis, IGA; Immunoglobulin A Nephropathy
Sites: Birmingham, Alabama; Los Angeles, California; Orlando, Florida · 19 sites in all
Maze TherapeuticsIndustry
NCT06830629 · 74 participants (planned) · Start Feb 5, 2025 · Primary completion Sep 2026
Drug: MZE829 · For: Proteinuric Kidney Disease
Sites: Decatur, Alabama; Huntsville, Alabama; Montgomery, Alabama · 79 sites in all
Chengdu Suncadia Medicine Co., Ltd.Industry
NCT07582133 · 380 participants (planned) · Start Jul 6, 2026 · Primary completion Jul 2029
Drug: HRS-5965 Capsules · For: Primary IgA Nephropathy
Sites: Beijing, China
Vera Therapeutics, Inc.Industry
NCT06983028 · 250 participants (planned) · Start Jul 7, 2025 · Primary completion Nov 2027
Drug: Atacicept · For: pMN; IgAN; Nephrotic Syndrome and 2 more
Sites: Brisbane, California
- A Study to Evaluate the Long-Term Safety and Efficacy of HSK39297 Tablets in Primary IgA NephropathyRecruiting
Haisco Pharmaceutical Group Co., Ltd.Industry
NCT07616700 · 73 participants (planned) · Start Aug 25, 2025 · Primary completion Dec 5, 2026
Drug: HSK39297 200mgQD; HSK39297 300mgQD · For: IgA Nephropathy (IgAN)
Sites: Beijing, China · 2 sites in all
Guangdong Hengrui Pharmaceutical Co., LtdIndustry
NCT07354932 · 84 participants (planned) · Start Mar 9, 2026 · Primary completion Apr 2027
Drug: SHR-2173 injection; SHR-2173 injection and 2 more · For: Primary IgA Nephropathy
Sites: Guangzhou, China; Shanghai, China
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.